Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Daxor Corp DXR

Healthcare Medical Devices
Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific... see more

Recent & Breaking News (NDAQ:DXR)

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

GlobeNewswire March 25, 2024

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

GlobeNewswire March 22, 2024

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

GlobeNewswire March 18, 2024

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

GlobeNewswire March 18, 2024

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

GlobeNewswire March 11, 2024

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients

GlobeNewswire March 8, 2024

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

GlobeNewswire February 26, 2024

Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions

GlobeNewswire February 12, 2024

Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts

GlobeNewswire February 7, 2024

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting

GlobeNewswire January 29, 2024

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress

GlobeNewswire January 16, 2024

DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

GlobeNewswire January 9, 2024

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

GlobeNewswire January 2, 2024

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients

GlobeNewswire November 13, 2023

Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume

GlobeNewswire November 9, 2023

Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting

GlobeNewswire October 13, 2023

New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting

GlobeNewswire October 11, 2023

Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program

GlobeNewswire October 4, 2023

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023

GlobeNewswire September 27, 2023

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL'23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100®)

GlobeNewswire September 26, 2023